Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Ophthalmol. 2012;6:1633-8. doi: 10.2147/OPTH.S37252. Epub 2012 Oct 8.

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Author information

  • 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan ; Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan.

Abstract

PURPOSE:

We evaluated the 2-year efficacy of combined intravitreal ranibizumab (IVR) treatment and photodynamic therapy (PDT) for treatment-naïve polypoidal choroidal vasculopathy (PCV).

PATIENTS AND METHODS:

Twenty-two eyes of 22 Japanese patients with treatment-naïve PCV were prospectively recruited. All eyes had angiographic features of PCV according to indocyanine green angiography. The initial combination treatment regimen included a session of PDT with IVR. A total of three consecutive IVR treatments were given at 4-week intervals. Eyes were retreated with IVR or PDT at specific times. We evaluated the mean visual acuity and mean central retinal thickness (CRT) at 3, 6, 9, 12, 18, and 24 months after initial treatment.

RESULTS:

At month 9, visual acuity had improved by 5.7 letters (P = 0.10). Subsequently, mean visual acuity gradually decreased, and the difference from baseline was diminished to 2.9 letters at 24 months (P = 0.43). Mean CRT was significantly decreased from baseline over the 24-month follow-up (P < 0.05).

CONCLUSION:

With PDT combined with IVR for PCV, visual acuity improved during year 1, but the benefit decreased in year 2.

KEYWORDS:

photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab

PMID:
23109800
[PubMed]
PMCID:
PMC3474272
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk